Physician
Hematology
Dr. David H. Boldt, MD
|
|
Give Review
David Boldt works in the field of Hematology. He attended Tufts University School of Medicine. Tufts University School of Medicine is ranked 49 in research and 52 in primary care medicine He over the years received 1 awards: "Elected Member". David Boldt has written publications. He has 41 publications published with PubMed. The lastest paper is: 'Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribut...'
Publications
- Iron deprivation blocks multilineage haematopoietic differentiation by inhibiting induction of p21(WAF1/CIP1).
- Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic Leukemia.
- Cyclophosphamide followed by fludarabine for untreated Chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
- Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in Chronic lymphocytic leukaemia.
- Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and require...
- p21(CIP1/WAF1/SDI1) hypermethylation: an exciting new lead in ALL biology.
- Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron.
- Expression of different NF-kappaB pathway genes in dendritic cells (DCs) or macrophages assessed by gene expression profiling.
- A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human Leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in ...
- Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic Leukemia: a South...
- Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic Leukemia.
- A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic Leukemia.
- New perspectives on iron: an introduction.
- Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribut...
- Analysis of DNA binding proteins associated with hemin-induced transcriptional inhibition. The hemin response element binding protein is a heterogeneous complex that i...
- Tumor suppressor gene alteration in adult acute lymphoblastic Leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with ...
- Inhibition of tartrate-resistant acid phosphatase gene expression by hemin and protoporphyrin IX. Identification of a hemin-responsive inhibitor of transcription.
- Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
- Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter.
- Expression of Myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience.
- Regulation of protein kinase C (PKC) expression by iron: effect of different iron compounds on PKC-beta and PKC-alpha gene expression and role of the 5'-flanking regio...
- Detection of BCR-ABL fusion genes in adult acute lymphoblastic Leukemia by the polymerase chain reaction.
- Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with Lymphoma and multiple myeloma.
- Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron.
- Durable complete remission in a patient with refractory mediastinal non-seminomatous germ cell tumor after tandem high-dose chemotherapy and autologous bone marrow tra...
- Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological Cancers.
- A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
- Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT.
- A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcin...
- Induction of protein kinase C mRNA in cultured lymphoblastoid T cells by iron-transferrin but not by soluble iron.
- Transcriptional regulation of transferrin receptor expression by cultured lymphoblastoid T cells treated with phorbol diesters.
- Phase I clinical trial of carbetimer.
- Disparity between expression of transferrin receptor ligand binding and non-ligand binding domains on human lymphocytes.
- Phorbol diesters and transferrin modulate lymphoblastoid cell transferrin receptor expression by two different mechanisms.
- Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
- Wheat germ agglutinin decreases expression of the T8 antigen on human peripheral mononuclear cells.
- Cell surface alpha 1-protease inhibitor on human peripheral mononuclear cells in culture.
- Interaction of wheat germ agglutinin with human peripheral blood mononuclear cells. Binding kinetics and flow microfluorometric analysis.
- Chronic lymphatic leukemia (CLL): cell surface changes detected by lectin binding and their relation to altered glycosyltransferase activity.
- Leukemic reticuloendotheliosis: "hairy cell Leukemia," functional and structural features of the abnormal cell in a patient with profound leukocytosis.
Schools
Tufts University
Barnes Jewish Hospital
Conditions Treated
- Anemia
- Chronic Myeloid Leukemia (CML)
- Colorectal Cancer
- Cryoglobulinemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Cross Blue Shield
- Cigna
- Commercial Insurance Company
- GEHA
- Humana
- Medicaid
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Elected Member
Education
-
Washington University - Barnes-Jewish Hospital -
Tufts University School of Medicine
Hospital
-
South Texas Veterans Health Care System
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124223565 |
| Last Name Of The Provider | BOLDT |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Francisco C. Rodriguez, MD |
|
|
Dr. Lindsay L. Peterson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen C. Cohen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott C. Ulmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory J. Guzley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suneetha Challagundla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Friedman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Muralidhar Beeram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles H. Mims Jr., MD |
|
|
Dr. Charlotte N. Clare, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Haile, MD |
|
|
Dr. Erin E. Ezzell, DO |
|
|
Dr. Robert F. Setlik, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gladys I. Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth A. Bowhay, MD |
|
|
Dr. Benjamin J. George, MD
This Doctor is OpenDoctor Recommended.
|